Saint Prex, Switzerland – 21 June 2016 – The Ferring Innovation Grants Program, which is now open for applications, has been significantly expanded as part of Ferring’s continued commitment to investing in research and development (R&D).
An initiative of the Ferring Research Institute (FRI), the program provides annual grants of up to $100,000 for early stage research, with a focus on novel extracellular drug targets addressable with peptides or proteins within Ferring’s core therapeutic areas: reproductive health, gastroenterology, urology, and endocrinology.
Total funding for this year’s program has been increased from $250,000 to $950,000. Together with changes to the application process and grants structure, this will open up the program to more applicants from leading research centres.
“The Innovation Grants Program is part of our broader commitment to stimulating basic research, with the ultimate aim of developing innovative products that improve the lives of patients,” said Per Falk, Executive Vice President and Chief Scientific Officer, Ferring Pharmaceuticals.
“It’s tremendous to be able to tap into the wider research community for new ideas,” said Keith James, President of FRI and Senior Vice President, Research and Development. “The program gives us a powerful window on external innovation in
our therapeutic areas of interest.”
For more information on this year’s program, please visit: www.ferring-research.com/ferring-grants
- ENDS -
About Ferring Pharmaceuticals
Headquartered in Switzerland, Ferring Pharmaceuticals is a research-driven, specialty biopharmaceutical group active in global markets. The company identifies, develops and markets innovative products in the areas of reproductive health, urology, gastroenterology, endocrinology and orthopaedics. Ferring has its own operating subsidiaries in nearly 60 countries and markets its products in 110 countries. To learn more about Ferring or its products please visit www.ferring.com
For further information:
Tel. +41 58 301 00 51
Tel. +41 58 301 00 53